Biosimilar Development and Commercialization

Introduction

Duration

Who should attend this course?

Core Learning Areas

Features

Related Courses

About Biosimilar Industry

The Advanced Certification in Biosimilar Development and Commercialization is a comprehensive online certification program designed to provide strategic, scientific, regulatory, and commercial understanding of the rapidly growing global biosimilar industry.

“Master the Complete Journey of Biosimilar Development, Regulatory Strategy & Global Commercialization.”

As biosimilars continue to reshape the biopharmaceutical market, organizations increasingly require professionals who can understand the complete biosimilar ecosystem — from product development and regulatory pathways to commercialization, market access, pricing, reimbursement, forecasting, and lifecycle strategy.

Therefore, this program has been strategically designed to bridge the gap between:

Biosimilar Development
Regulatory Affairs
Commercialization Strategy
Market Access
HEOR
Pricing & Reimbursement
Forecasting
Portfolio & Lifecycle Management

Different from traditional training

Unlike traditional biosimilar training programs that focus only on development or regulatory aspects, RYD-145 delivers an integrated industry-oriented learning approach aligned with real-world biosimilar business operations.

Furthermore, the course simplifies complex biosimilar concepts into structured and easy-to-understand learning modules, making it highly suitable for working professionals, corporate teams, and professionals transitioning into the biosimilar sector.

The program provides strategic exposure to:

Biosimilar Development Lifecycle
Analytical Similarity & Comparability
Immunogenicity Concepts
Global Biosimilar Regulatory Frameworks
Biosimilar CMC Strategy
Market Access & HEOR
Pricing & Reimbursement Models
Biosimilar Forecasting
Commercial Launch Strategy
Competitive Intelligence
Tender Market Dynamics
Portfolio & Lifecycle Management
AI in Biosimilar Strategic Operations

Additionally, participants will gain understanding of major global biosimilar markets including:

United States (FDA)
Europe (EMA)
United Kingdom (MHRA)
Japan (PMDA)
Canada
ASEAN
LATAM
Middle East
Emerging Biosimilar Markets

Course Snapshot

Course Code: RYD-145
Title: Executive PG Certification in Biopharma Global Business (EPBioGB)
Type of the course: Self paced Online Course. Hence this course can be accessed online across anywhere 24×7. Moreover, you can attend the course at your convenience in your flexible time. For example, if you want to attend the session at 11 pm at night, you can do that.
Course Duration : 1 Month. Free extendable upto 3 month (1 month plus additional 2 month access).
Course Certification: Certificate will be provided at the end of the successful completion of the course.

Why Join This Program?
This executive-level course bridges science, strategy, and business — helping you transform from a scientific or commercial professional into a global biopharma business strategist.

The program follows a professionally structured online learning model supported by:

Real-world biosimilar case studies
Strategic commercialization exercises
Regulatory strategy simulations
Market access scenarios
Forecasting workshops
Industry-oriented assignments

As a result, participants will develop practical and strategic competencies required for modern biosimilar development and commercialization functions.

1-Month Intensive Program

Extended Learning Access: Up to 3 Months (No Additional Cost).
Flexible Learning Structure for Working Professionals
Self-Paced Professional Learning Model
Suitable for Individual & Corporate Enrollment
Additional Learning Extension Available Beyond 3 Months on Payment of Applicable Extension Fees
Extended Access Support Available for Continued Learning, Revision & Program Completion Requirements
Designed to Support Flexible Professional Upskilling & Long-Term Learning Convenience

Who should attend this course?

Regulatory Affairs Professionals
Biosimilar & Biopharmaceutical Development Teams
Market Access & HEOR Professionals
Medical Affairs Professionals
Commercial Strategy & Product Management Teams
Pricing & Reimbursement Professionals
Forecasting & Market Intelligence Professionals
Business Development & Licensing Teams
IP Landscaping & Patent Strategy Professionals
Competitive Intelligence Professionals
Portfolio & Lifecycle Management Teams
Corporate Biosimilar Teams
Biopharmaceutical Industry Professionals
Professionals Transitioning into the Biosimilar Industry
Life Science & Biotechnology Professionals
Strategic Business & Commercial Operations Professionals
Professionals Seeking Biosimilar Industry Upskilling
Organizations Planning Corporate Biosimilar Capability Development

What You’ll Learn in This Exclusive Program:

This program designed to build strategic competencies across biosimilar development, regulatory affairs, commercialization, market access, and lifecycle management.

Biosimilar Industry Foundation & Global Landscape

The program begins with a strong foundation in biosimilars and similar biologics, helping participants understand the overall biosimilar ecosystem and its strategic importance in the modern biopharmaceutical industry. Participants will learn the difference between innovator biologics and biosimilars, how biosimilars are transforming healthcare accessibility, and the major growth drivers shaping global biosimilar markets. The course will also provide understanding of global market trends, commercial opportunities, industry challenges, competitive market dynamics, and the future direction of the biosimilar industry.

Biosimilar IP Landscaping & Patent Dance Strategy

Following the commercialization strategy section, the program will provide detailed exposure to biosimilar intellectual property (IP) strategy, patent landscaping, and patent litigation frameworks that significantly influence biosimilar market entry and commercialization timelines. Participants will understand how patent ecosystems impact biosimilar development strategy, launch planning, competitive positioning, and global market access decisions.

Biosimilar Development Lifecycle

Participants will gain a comprehensive understanding of the biosimilar development process, starting from analytical development through clinical and commercialization stages. The course will cover analytical similarity assessment, comparability exercises, Critical Quality Attributes (CQAs), manufacturing concepts, process development, stability considerations, immunogenicity assessment, and clinical development strategy. In addition, learners will understand the scientific and operational challenges involved in biosimilar product development and lifecycle planning.

Biosimilar Regulatory Affairs & Global Compliance

This section focuses on the regulatory pathways and compliance requirements associated with biosimilars across major global markets. Participants will learn how biosimilar regulations differ from generic drug pathways and how global agencies evaluate biosimilar products. The course will cover US FDA biosimilar pathways, EMA biosimilar regulations, MHRA and PMDA expectations, emerging market regulatory approaches, biosimilar dossier strategies, CMC documentation, labeling considerations, pharmacovigilance requirements, and lifecycle regulatory management practices.

Biosimilar Commercialization Strategy

The program provides detailed exposure to biosimilar commercialization and strategic market planning. Participants will understand how biosimilar products are commercially positioned in competitive markets and how organizations develop market penetration strategies. The course will cover biosimilar launch planning, physician adoption strategy, commercial positioning, brand differentiation, multi-market expansion planning, commercialization risk management, and strategic approaches to increasing market adoption of biosimilar products.

Market Access, HEOR & Value Strategy

Participants will learn how market access and HEOR play a critical role in biosimilar adoption and reimbursement success. The course will explain how value demonstration strategies are developed for biosimilars and how payers evaluate pricing and reimbursement decisions. Learners will gain understanding of cost-effectiveness analysis, budget impact models, Health Technology Assessment (HTA), Real-World Evidence (RWE), payer evidence expectations, reimbursement pathways, and tender market dynamics used in various global markets.

Pricing, Reimbursement & Biosimilar Forecasting

This section focuses on commercial decision-making processes associated with biosimilar pricing and forecasting. Participants will understand different biosimilar pricing models, reimbursement systems, competitive pricing strategies, tender-driven pricing dynamics, and commercial access strategies. Furthermore, the course will provide exposure to biosimilar market valuation methods, demand forecasting models, revenue forecasting approaches, market opportunity analysis, and commercial analytics used for strategic business planning in the biosimilar sector.

Portfolio & Lifecycle Management

The course also covers strategic portfolio and lifecycle management concepts that are essential for long-term biosimilar business growth. Participants will understand how organizations manage biosimilar portfolios, plan lifecycle strategies, evaluate market expansion opportunities, and differentiate biosimilar products within highly competitive markets. This section will also include concepts related to patent and exclusivity considerations, strategic licensing opportunities, alliance models, and risk assessment frameworks for biosimilar business sustainability.

AI & Digital Transformation in Biosimilars

As digital transformation continues to influence the biopharmaceutical industry, the course introduces the role of AI and advanced analytics in biosimilar operations. Participants will learn how AI can support regulatory operations, forecasting, competitive intelligence, strategic documentation, market analysis, and decision-making. Additionally, the course will explore emerging digital trends that are influencing biosimilar commercialization, operational strategy, and global business management practices.

Competitive Intelligence & Strategic Business Understanding

Participants will gain understanding of how biosimilar organizations analyze competitive markets, monitor industry movements, and develop strategic business plans. The course will cover competitor benchmarking, market intelligence approaches, opportunity mapping, strategic positioning, commercial risk evaluation, and business expansion strategy. This section is designed to strengthen strategic thinking capabilities within biosimilar commercial and regulatory functions.

Practical Industry Learning & Simulations

The program is designed with a strong practical learning orientation. Therefore, participants will be exposed to real-world biosimilar case studies, commercialization exercises, forecasting workshops, regulatory simulations, market access scenarios, lifecycle strategy exercises, and strategic planning activities. These practical components are intended to help professionals understand how biosimilar concepts are implemented within actual pharmaceutical and biopharmaceutical industry environments.

Why This Course Stands Out

Most biosimilar courses primarily focus on scientific development or regulatory pathways alone.

However, the global biosimilar industry today requires professionals who can understand both development and commercialization dynamics simultaneously.

Therefore, RYD-145 has been specifically designed to integrate:

Development
Regulatory Affairs
Commercialization
Market Access
HEOR
Pricing
Forecasting
Strategic Lifecycle Management

within one comprehensive executive certification program.

This integrated approach makes the course highly aligned with real-world biopharmaceutical industry operations and corporate upskilling requirements.

Few other courses on Biologics

Career in Biosimilar Industry

The biosimilar industry is rapidly emerging as one of the fastest-growing segments within the global biopharmaceutical sector. As healthcare systems increasingly focus on improving affordability and access to biologic therapies, the demand for biosimilars continues to expand across major global markets including the United States, Europe, Asia-Pacific, LATAM, and emerging economies.

Consequently, pharmaceutical and biopharmaceutical organizations are actively seeking professionals who possess integrated understanding across biosimilar development, regulatory affairs, commercialization, market access, pricing, HEOR, forecasting, and lifecycle management.

Unlike conventional pharmaceutical careers that are often limited to specific functional roles, the biosimilar industry offers multidisciplinary career opportunities across scientific, regulatory, strategic, and commercial domains.

Why Biosimilars Are Creating Massive Career Opportunities

Biologics represent one of the largest and fastest-growing therapeutic categories globally. As major biologic products lose patent exclusivity, biosimilars are becoming critical for reducing treatment costs while expanding patient access.

Therefore, companies worldwide are investing heavily in:

Biosimilar Development
Manufacturing Expansion
Regulatory Submissions
Commercial Launches
Market Access Strategy
Global Commercialization
Portfolio Expansion
Strategic Licensing & Partnerships

This rapid expansion is generating strong demand for skilled biosimilar professionals across multiple functions.

Section 1Biosimilar Development Project Management & Timeline

Lecture 1R&D Process - Discovery to Commercialization

Lecture 2Investigational New Drug Application (INDA)

Lecture 3New Drug Application (NDA)

Lecture 5Basic concept and understanding of the Generic Drug

Lecture 6Abbreviated New Drug Application (ANDA)

Lecture 7Abbreviated Biosimilar Application - 351(k): Advance Strategic Planning Process : Originator Vs. Biosimilar Development and Regulatory Approval Process | Reference Biologic | Purple Book | Data Requirements

Lecture 8505(j) ANDA, 505(b)(2) NDA, 505(b)(1) NDA

Lecture 9Vaccine development and approval Process

Lecture 10Handling of orange book

Lecture 11Purple Book: Significance | Searching | Assignments

Lecture 12Clinical Trials Terminologies

Lecture 13Clinical Trial Protocol Writing

Lecture 14Ethics in Clinical Research

Lecture 15Informed Consent | Practical Training on preparing ICF | Ready Templates

Lecture 16Importance of Project Management in Biopharmaceutical Industry

Lecture 17Traditional Project Management Vs. BioPharma Project Management | Key Differences | Different Parameters

Lecture 18Key Comparison of Traditional and Pharma Project Management

Lecture 19Regulatory Influences on Biopharma Project Timelines and Deliverables

Lecture 20Case Study: Managing a New Drug Development Project with Strict Regulatory Timelines

Lecture 21Core Identified Phases of the Pharmaceutical Project Lifecycle

Lecture 22Terminologies of Pharmaceutical Project Management

Lecture 23Project Tracking

Lecture 24Asset Tracking

Lecture 25Role and Responsibility of Project Leader

Lecture 26Project Constraint & Effective management of Project Constraint | Role of Project Manager

Lecture 27Critical Success Factor in Drug Development Projects

Lecture 28Project Management Case Study | Exploring the Project Tools Used in real life project

Section 2Biosimilar Management and Regulation

Lecture 29Introduction : Biopharmaceuticals

Lecture 30Classification of Biopharmaceutical

Lecture 31Important Concept regarding Biopharmaceuticals

Lecture 32Introduction to Biologics and Biosimilar | Key differences | Concept of Reference Product

Lecture 33Key features of Biologic | Differences in Chemical Drug Vs. Biologic Drugs

Lecture 34Principle of Naming of Biologic | Understanding on MAB naming system

Lecture 35Global Biopahrma Market Trends

Lecture 36Recombinant protein

Lecture 37Monoclonal Antibodies Vs. Polyclonal Antibodies

Lecture 38Monoclonal Antibodies

Lecture 39Synthetic Immunomodulators

Lecture 40Production of Monoclonal Antibodies

Lecture 41Cytokines

Lecture 42Interferon

Lecture 43Erythropoiesis-stimulating agent

Lecture 44Vaccine development and approval Process

Lecture 45Biosimilar Development Process

Lecture 46Strategic Consideration for Biosimilar Development

Lecture 47Bio-Manufacturing Process Information

Lecture 48Studies required for approval of biosimilar

Lecture 49REMS Strategic Planning

Lecture 50ATMPs | Types and Classification | Regulatory Mechanism

Lecture 51mAB - At a glance

Lecture 52ATMPs - at a glance

Lecture 56Studies required for approval of biosimilar

Lecture 57Comparability of Biologics | Different Categories of Comparability | General Principles

Lecture 58CQA (Critical Quality Attribute) and CPP (Critical Process Parameter)

Section 3Biosimilar Market Access

Lecture 59Biosimilar Approval and Patent Management | Strategic Pathway of Patent Negotiation and Litigation in Biosimilar Approval | Patent Dance | FAQs on Biologic Patent Management

Lecture 60Biosimilar launch case study | Patent Dance Framework

Lecture 61Biosimilar Launch Framework

Lecture 62Biosimilar 180 Day Notice

Lecture 633(A) List | Significance | Importance | How to interpret

Lecture 64Steps to win over innovator patents | Step wise planning

Lecture 65Biosimilar Launch Project Roadmap with defined stages of project

Lecture 66Timing of Biosimilar Submission and Approvals | Two Scenario based timeline assessments

Lecture 67Hands on Training on Reference Biologic Patent | Classify RPS Biologic Patents | Case Simulation

Lecture 68How to work on RPS’s Patent | Walkthrough | Case Study

Lecture 69Biosimilar Launch Project With Milestones

Lecture 70Analysis of Biologic Patents | Work Assignments

Lecture 71Biologic Patent Insight Worksheet

Lecture 72Patent Thickets | Concept | Implication | Case Based Learning

Section 4Biosimilar Pricing | Formulary Placement

Lecture 73Introduction to Market Access | Objectives | Various Key Terminologies | Steps of Market Access | Understanding on Pricing and Reimbursement

Lecture 74Market Access Functions : Role and Responsibilities | Key Job Areas | Understanding Job Description

Lecture 75Market Access Strategic Planning

Lecture 76Indication Sequencing | Indication Prioritization | Development of Indication Timeline | Indication Matrix | Value Based Indication Prioritization

Lecture 77Indication Prioritization Case Study

Lecture 78Market Access Value Dossier : What it is | Significance | Components | What to include

Lecture 79AMCP Market Access Value Dossier Preparation

Lecture 80Drug Pricing Methodologies

Lecture 81Sales Forecasting in Life Science Industry

Lecture 82New Product Forecast Algorithm

Lecture 83Patient Based Forecasting Model | Applying more filters and variables

Lecture 84Prescription Based Forecasting Model | Differences between Patient Based and Prescription Based Forecasting Model | Which model to use and when?

Lecture 85Prevalence Vs. Incidence Model

Lecture 86EPI Based Forecasting | Sales Based Forecasting | When and where to apply which forecasting model

Lecture 87Sales Forecasting Tools | New Product Forecasting | In Market Forecasting

Lecture 88Market Size Assignment 1 [Oncology Brand] - Applying sales forecasting tools to carry out next 6 years sales forecast | Excel Based Model

Lecture 89Market Size Assignment 2 [Asthma Brand] - Applying sales forecasting tools to carry out multiple years sales forecast | Excel Based Model

Lecture 91Patient Based Model Vs. Patient Flow Model | Critical Differences in Model | Concept of Black Box in Patient Flow Model | Application of both model

Lecture 92Concomitancy and polypharmacy | How it alter the basic forecasting algorithm | Practical Working | Comorbidity

Lecture 94Simulation on Bottom-up forecasting

Lecture 95Assessment on Bottom-up forecasting

Lecture 96Oncology Brand Forecasting

Lecture 97Authorized Geenric

Lecture 98Branded Generics | Differences from Authorized and Unbranded Generics | Strategic planning for formulary placement

Section 5Biosimilar Advanced Strategic Management

Lecture 99Patents Vs. exclusivity

Lecture 101Orphan Drug Designation

Lecture 102USFDA expedited programs

Lecture 103Advance study on Para IV Filing

Lecture 104Para IV Notices

Lecture 105Evergreening - Patent Life Extension Strategies

Lecture 106Pay For Delay Strategy

Lecture 107Compulsory Licensing

Lecture 108Licensing & Technology Transfer

Lecture 109In-Licensing Vs. Outlicensing

Lecture 110LOE Strategies for Innovator Brands with case study

Lecture 111Drug Repurposing

Lecture 112Advance understanding of the portfolio Management

Section 6Advance Biopharma Regulations and Submission Management

Lecture 113505(j) ANDA, 505(b)(2) NDA, 505(b)(1) NDA

Lecture 114Advance Learning on 505B2 Pathway

Lecture 115Chemistry, Manufacturing & Controls

Lecture 116Common Technical Document (CTD)

Lecture 117Introduction to Electronic Common Technical Document (ECTD)

Lecture 118Advance Practical Training on Dossier Preparation focusing on drug registration in export countries

Lecture 119Modules on Stability Study : Stability Study - Fundamental Understanding | Interchangebility | Reports | API & FPP Stability Study

Lecture 120Importance of effective dossier management

Lecture 121Certificate of Analysis

Lecture 122Detailed Understanding on ANDA Submission Dossier

Lecture 123Prior Approval Submission

Lecture 124Detailed Understanding on 505(b)(2) VS. Suitability Petition : Case Based Learning

Lecture 125NCE Vs. 505b2 application - Case Based Learning

Lecture 126FTF - 180 Days Exclusivity - Case Based Learning

Lecture 127Classic case study of the 505b2 filing : Case Based Learning

Lecture 128Strategic Planning in Combating 30 months stay strategies of innovator company- Case Based Learning

Lecture 129Discussion on 85 common deficiency in CTD submission dossier

Lecture 130Electronic Batch Record for effective compliance management | Key Understanding | Functionalities | Importance in managing data integrity

Lecture 131PKPD in Drug Discovery | PK-PD trial | Understanding PKPD from regulatory perspective in drug approval process

Lecture 132Bioequivalence Study | Study design | Different types of BE Studies

Lecture 134Establishment Inspection Report | 483 Observations | USFDA Warning Letter | Handling of FDA inspection | Closing of Warning Letter

Lecture 135Data Integrity issues in Pharmaceutical Industry

Section 7Real World Data and Real World Evidence

Lecture 136Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence?

Lecture 137RWD and RWE | Potential sources of RWE | Traditional RCTs vs. RWE | Case Study - RWE Programs | Influencing HCP decision-making

Lecture 138RWD and RWE in Product Lifecycle Management

Lecture 139RWD and RWE - Fit to use | Assessment

Lecture 140RWD data sources | Different types | Detailed understanding of each class

Lecture 141RWD Study Design

Lecture 142RWE Published Tool | Insights on commonly used tools

Lecture 143RWD Study Design

Lecture 144Healthcare Reimbursement Models : Value Based Care | Fee for Service (FFS) Model | Other Reimbursement Models

Lecture 145HEOR Consensus Narrative Review

Lecture 146Electronic Patient Data | EMR | EHR | Differences | Software architecture and characteristics

Lecture 148RWD Characteristics

Lecture 149RCT vs. RWE Comparison | Case Based Analysis

Lecture 150RCT and RWE Comparison

Section 8Working on Real World Datasets

Lecture 151Introduction to Healthcare Datasets

Lecture 152Dataset 1: Claims Data (Insurance)

Lecture 153Dataset 2: Retail Pharmacy Prescription Data

Lecture 154Dataset 3: Longitudinal Patient Data

Lecture 155Characteristics of Different Set of Healthcare Data

Lecture 156Reimbursement and Pricing Datasets

Lecture 157RWE Data Sources & Quality Considerations Checklist | Case Based Analysis

Lecture 158Triangulation and benchmarking | Enhancing Data Validation Through Cross-Referencing

Lecture 159RWD & RWE Case Database

Lecture 160RWE Large Dataset for Data Crunching Exercises |Data cleaning & preprocessing | Comparative Effectiveness Analysis

Section 9Biosimilar Business Development and Licensing

Lecture 161Training on Basic Finance | Understanding Financial Statment | Income Statement | Balance Sheet | Cash Flow Statement

Lecture 162Moving Average | Moving Annual Total | YTD | How to calculate

Lecture 163Compound Annual Growth Rate | CAGR Calculation

Lecture 164Business Development Job Functionality | Strategic Planning Process | Knowledge Area of Business Development | Lead targeting | Licensing term sheets

Lecture 165Portfolio Management Process | Portfolio Characteristics | Portfolio Analysis | Balancing the Portfolio | BD and Strategic Planning Department

Lecture 166Identifying the corporate Need of business development | Objective – Strategy - Tactics | Portfolio constraints | SWOT | Numerical SWOT

Lecture 168Numerical SWOT Practical training

Lecture 170Market Size Determination - Market Share | Relative Market Share | Total Vs. Actual Vs. Penetrated Market

Lecture 171Forecasting : Tools and Techniques

Lecture 172Market Sizing & Forecasting Case Study

Lecture 174Average Royalty Rate

Lecture 175Factor affecting the Royalty Rate in Pharmaceutical and Biopharmaceutical Deal

Lecture 176Distribution Licensing | Geography | Indication Splitting | Exclusive and Non-Exclusive Licensing | Sub Licenses

Lecture 178Joint Ventures in Pharmaceutical and Biopharmaceutical Industry

Lecture 179SPECIAL PURPOSE VEHICLES (SPV)

Lecture 180Indication Splitting | Concept | Implementation feasibility analysis

Lecture 181Types of Deals from Discovery to Commercialization

Lecture 182What are the fundamental areas of business development

Lecture 183Licensing Term Sheet | Content Structuring | Sample Term Sheet

Lecture 184Licensing Payment Schedule | Case Study

Lecture 186Valuation Methods: EBITDA method of valuation | Enterprise Value and Enterprise Multiple Calculation

Lecture 187Negotiation Skill Training for BD personnel | Mind Mapping Tools | Practical Case Based Learning | Do and Don’ts in Pharma Business development Negotiations | Role of Scribes

Lecture 188Business Development Simulation and Decision Making | Early Stage VS. Late Stage Valuation Methodology | Stair Step Model

Lecture 190Benchmarking | Benchmarking through consortium | How to use benchmarking for drug discovery development projects

Lecture 191DCF Calculation : Concept and Calculation - Step by step understanding

Lecture 192Net Present Value (NPV) method : Calculation

Lecture 193Risk-Adjusted Discount Rate Method - Calculation | Concept of Risk Premium

Lecture 194Valuation Metric - P/E Ratio and EPS : Calculation

Lecture 195Comparable Company Analysis method : Calculation

Lecture 197Pipeline Benchmarking | Significance and Importance in Bio Pharma BD&L | Analyzing sample portfolio | Comparative outcome in business development

Lecture 198Comparative pipeline benchmarking analysis | Level of Benchmarking | Primary - Secondary - Tertiary Benchmarking Metrics | Case Based Analysis of three companies comparative pipeline benchmarking

Lecture 199Pipeline Diversity Scores | Significance | How to Calculate | Comparative Study of Pipeline Diversity Scores

Lecture 200Assignment: Prepare real time tracker

Lecture 201Research Productivity Index | Concept | Significance | Calculation Methodology | Comparative RPI benchmarking Exercise

Lecture 202WACC in Biopharma Valuation | Significance | WACC benchmarking

Lecture 203WACC Calculation | Step by Step Calculation | Insight on WACC components

Lecture 204rNPV Model | Step by Step Calculation | Insight on Probability and Cumulative Probability | Factoring WACC for Discounting

Lecture 205Probability and Cumulative Probability | Calculation | Benchmarking | Factoring for WACC and rNPV

Lecture 206Real Options Valuation (ROV) for Biopharma assets | Model Development | Calculation | Case Based Insight in the context of inlicensing and outlicensing | Early stage asset valuation with ROV

Lecture 207ROV Scenario Based Case Study

Lecture 208Biotech Decision Tree Model with Decision Reasoning

Biosimilar Development and Commercialization

Download All Course Catalogue

Your form has been submitted

Request for Course Demo Session

Your form has been submitted

Introduction

Duration

Who should attend this course?

Core Learning Areas

Features

Related Courses

About Biosimilar Industry

Different from traditional training

Course Snapshot

1-Month Intensive Program

Who should attend this course?

Biosimilar Industry Foundation & Global Landscape

Biosimilar IP Landscaping & Patent Dance Strategy

Biosimilar Development Lifecycle

Biosimilar Regulatory Affairs & Global Compliance

Biosimilar Commercialization Strategy

Market Access, HEOR & Value Strategy

Pricing, Reimbursement & Biosimilar Forecasting

Portfolio & Lifecycle Management

AI & Digital Transformation in Biosimilars

Competitive Intelligence & Strategic Business Understanding

Practical Industry Learning & Simulations

Why This Course Stands Out

Few other courses on Biologics

Career in Biosimilar Industry

Why Biosimilars Are Creating Massive Career Opportunities

Royed Training

Biosimilar Development and Commercialization

Please sign in first

Not a member?

Download All Course Catalogue

Your form has been submitted

Request for Course Demo Session

Your form has been submitted

Introduction

Duration

Who should attend this course?

Core Learning Areas

Features

Related Courses

About Biosimilar Industry

Different from traditional training

Course Snapshot

1-Month Intensive Program

Who should attend this course?

Biosimilar Industry Foundation & Global Landscape

Biosimilar IP Landscaping & Patent Dance Strategy

Biosimilar Development Lifecycle

Biosimilar Regulatory Affairs & Global Compliance

Biosimilar Commercialization Strategy

Market Access, HEOR & Value Strategy

Pricing, Reimbursement & Biosimilar Forecasting

Portfolio & Lifecycle Management

AI & Digital Transformation in Biosimilars

Competitive Intelligence & Strategic Business Understanding

Practical Industry Learning & Simulations

Why This Course Stands Out

Few other courses on Biologics

Career in Biosimilar Industry

Why Biosimilars Are Creating Massive Career Opportunities